Sign In

Login

Password

Forgot Password ? Sign Up

Cinarizina (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cinarizina" in Spanish language version.

refsWebsite
Global rank Spanish rank
32nih.gov
4th place
4th place
24doi.org
2nd place
2nd place
4archive.org
6th place
5th place
1who.int
195th place
173rd place
1web.archive.org
1st place
1st place
1nhs.uk
1,989th place
3,056th place

archive.org

doi.org

dx.doi.org

nhs.uk

nih.gov

ncbi.nlm.nih.gov

  • Terland, O.; Flatmark, T. (1999). «Drug-induced parkinsonism: Cinnarizine and flunarizine are potent uncouplers of the vacuolar H+-ATPase in catecholamine storage vesicles». Neuropharmacology 38 (6): 879-882. PMID 10465691. doi:10.1016/s0028-3908(98)00233-0. 
  • Singh, B. N. (1986). «The mechanism of action of calcium antagonists relative to their clinical applications». British Journal of Clinical Pharmacology. 21 Suppl 2 (Suppl 2): 109S-121S. PMC 1400740. PMID 3530295. 
  • Nicholson, A. N.; Stone, B. M.; Turner, C.; Mills, S. L. (2002). «Central effects of cinnarizine: Restricted use in aircrew». Aviation, space, and environmental medicine 73 (6): 570-574. PMID 12056673. 
  • Wilder-Smith, C. H.; Schimke, J.; Osterwalder, B.; Senn, H. J. (1991). «Cinnarizine for prevention of nausea and vomiting during platin chemotherapy». Acta oncologica (Stockholm, Sweden) 30 (6): 731-734. PMID 1958394. doi:10.3109/02841869109092448. 
  • Pianese, C. P.; Hidalgo, L. O.; Gonz??Lez, R. H.; Madrid, C. E.; Ponce, J. E.; Ram??Rez, A. M.; Mor??n, L. M.; Arenas, J. E.; Rubio, A. T.; Uribe, J. O.; Abiuso, J. ?; Hanuch, E.; Alegr??a, J.; Volpi, C.; Flaskamp, R.; Sanju??n, A. P. ?A.; g??Mez, J. M. G. ?A.; Hern??Ndez, J.; Pedraza, A.; Quijano, D.; Mart??Nez, C.; Casta??Eda, J. R. ?N.; Guerra, O. J. C. ?O.; f, G. V. (2002). «New approaches to the management of peripheral vertigo: Efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study». Otology & neurotology : official publication of the American Otological Society, American Neurotology Society \and] European Academy of Otology and Neurotology 23 (3): 357-363. PMID 11981396. doi:10.1097/00129492-200205000-00023. 
  • Arab, S. F.; Düwel, P.; Jüngling, E.; Westhofen, M.; Lückhoff, A. (2004). «Inhibition of voltage-gated calcium currents in type II vestibular hair cells by cinnarizine». Naunyn-Schmiedeberg's Archives of Pharmacology 369 (6): 570-575. PMID 15138660. doi:10.1007/s00210-004-0936-3. 
  • Lucertini, M.; Mirante, N.; Casagrande, M.; Trivelloni, P.; Lugli, V. (2007). «The effect of cinnarizine and cocculus indicus on simulator sickness». Physiology & Behavior 91 (1): 180-190. PMID 17434541. doi:10.1016/j.physbeh.2007.02.008. 
  • Ganança, M. M.; Caovilla, H. H.; Munhoz, M. S.; Ganança, C. F.; Da Silva, M. L.; Serafini, F.; Ganança, F. F. (2007). «Optimizing the pharmacological component of integrated balance therapy». Brazilian journal of otorhinolaryngology 73 (1): 12-18. PMID 17505593. doi:10.1016/s1808-8694(15)31116-2. 
  • Haasler, T.; Homann, G.; Duong Dinh, T. A.; Jüngling, E.; Westhofen, M.; Lückhoff, A. (2009). «Pharmacological modulation of transmitter release by inhibition of pressure-dependent potassium currents in vestibular hair cells». Naunyn-Schmiedeberg's Archives of Pharmacology 380 (6): 531-538. PMID 19830405. doi:10.1007/s00210-009-0463-3. 
  • Yates, B. J.; Miller, A. D.; Lucot, J. B. (1998). «Physiological basis and pharmacology of motion sickness: An update». Brain Research Bulletin 47 (5): 395-406. PMID 10052567. doi:10.1016/s0361-9230(98)00092-6. 
  • Gil, A.; Nachum, Z.; Tal, D.; Shupak, A. (2012). «A Comparison of Cinnarizine and Transdermal Scopolamine for the Prevention of Seasickness in Naval Crew». Clinical Neuropharmacology 35 (1): 37-39. PMID 22139622. doi:10.1097/WNF.0b013e31823dc125. 
  • Saletu, B.; Grünberger, J. (1980). «Antihypoxidotic and nootropic drugs: Proof of their encephalotropic and pharmacodynamic properties by quantitative EEG investigations». Progress in neuro-psychopharmacology 4 (4–5): 469-489. PMID 7012879. doi:10.1016/0364-7722(80)90017-x. 
  • Towse, G. (1980). «Cinnarizine--a labyrinthine sedative». The Journal of laryngology and otology 94 (9): 1009-1015. PMID 7000939. doi:10.1017/s0022215100089787. 
  • Teive, H. L. A. G.; Troiano, A. R.; Germiniani, F. M. B.; Werneck, L. C. (2004). «Flunarizine and cinnarizine-induced parkinsonism: A historical and clinical analysis». Parkinsonism & Related Disorders 10 (4): 243-245. PMID 15120099. doi:10.1016/j.parkreldis.2003.12.004. 
  • Poignet, H.; Beaughard, M.; Lecoin, G.; Massingham, R. (1989). «Functional, Behavioral, and Histological Changes Induced by Transient Global Cerebral Ischemia in Rats: Effects of Cinnarizine and Flunarizine». Journal of Cerebral Blood Flow & Metabolism 9 (5): 646-654. PMID 2777934. doi:10.1038/jcbfm.1989.92. 
  • Arieli, R.; Shupak, A.; Shachal, B.; Shenedrey, A.; Ertracht, O.; Rashkovan, G. (1999). «Effect of the anti-motion-sickness medication cinnarizine on central nervous system oxygen toxicity». Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc 26 (2): 105-109. PMID 10372430. 
  • Emanuel, M. B.; Chamberlain, J. A.; Whiting, S.; Rigden, B. G.; Craven, A. H. (1979). «Cinnarizine in the treatment of chronic asthma». British Journal of Clinical Pharmacology 7 (2): 189-195. PMC 1429430. PMID 367414. doi:10.1111/j.1365-2125.1979.tb00920.x. 
  • Tosoni, C.; Lodi-Rizzini, F.; Cinquini, M.; Pasolini, G.; Venturini, M.; Sinico, R. A.; Calzavara-Pinton, P. (2009). «A reassessment of diagnostic criteria and treatment of idiopathic urticarial vasculitis: A retrospective study of 47 patients». Clinical and Experimental Dermatology 34 (2): 166-170. PMID 18681869. doi:10.1111/j.1365-2230.2008.02891.x. 
  • Kariya, S.; Isozaki, S.; Masubuchi, Y.; Suzuki, T.; Narimatsu, S. (1995). «Possible pharmacokinetic and pharmacodynamic factors affecting parkinsonism inducement by cinnarizine and flunarizine». Biochemical Pharmacology 50 (10): 1645-1650. PMID 7503767. doi:10.1016/0006-2952(95)02057-8. 
  • Fabiani, G.; Pastro, P. C.; Froehner, C. (2004). «Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine». Arquivos de neuro-psiquiatria 62 (3B): 784-788. PMID 15476069. doi:10.1590/S0004-282X2004000500008. 
  • Serrano, A.; Menendez, J.; Casarejos, M.; Solano, R.; Gallego, E.; Sanchez, M.; Mena, M.; Garciadeyebenes, J. (2005). «Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice». Neuropharmacology 49 (2): 208-219. PMID 15993444. doi:10.1016/j.neuropharm.2005.03.003. 
  • Turner, D.; Lurie, Y.; Finkelstein, Y.; Schmid, T.; Gopher, A.; Kleid, D.; Bentur, Y. (2006). «Pediatric Cinnarizine Overdose and Toxicokinetics». Pediatrics 117 (5): e1067-e1069. PMID 16636115. doi:10.1542/peds.2005-2059. 
  • Spagnoli, A.; Tognoni, G. (1983). «'Cerebroactive' drugs. Clinical pharmacology and therapeutic role in cerebrovascular disorders». Drugs 26 (1): 44-69. PMID 6349963. doi:10.2165/00003495-198326010-00003. 
  • Castañeda-Hernández, G.; Vargas-Alvarado, Y.; Aguirre, F.; Flores-Murrieta, F. J. (1993). «Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers». Arzneimittel-Forschung 43 (5): 539-542. PMID 8328998. 
  • Nowacka-Krukowska, H.; Rakowska, M.; Neubart, K.; Kobylińska, M. (2007). «High-performance liquid chromatographic assay for cinnarizine in human plasma». Acta poloniae pharmaceutica 64 (5): 407-411. PMID 18540159. 
  • Kornhuber, J.; Henkel, A. W.; Groemer, T. W.; Städtler, S.; Welzel, O.; Tripal, P.; Rotter, A.; Bleich, S. et al. (2010). «Lipophilic cationic drugs increase the permeability of lysosomal membranes in a cell culture system». Journal of Cellular Physiology 224 (1): 152-164. PMID 20301195. doi:10.1002/jcp.22112. 
  • Emanuel, M. B. (1979). «Specific calcium antagonists in the treatment of peripheral vascular disease». Angiology 30 (7): 454-469. PMID 464337. doi:10.1177/000331977903000704. 
  • Shi, S.; Chen, H.; Lin, X.; Tang, X. (2010). «Pharmacokinetics, tissue distribution and safety of cinnarizine delivered in lipid emulsion». International Journal of Pharmaceutics 383 (1–2): 264-270. PMID 19770029. doi:10.1016/j.ijpharm.2009.09.025. 
  • Klein, M.; Musacchio, J. M. (1989). «High affinity dextromethorphan binding sites in guinea pig brain. Effect of sigma ligands and other agents». The Journal of Pharmacology and Experimental Therapeutics 251 (1): 207-215. PMID 2477524. 
  • Silver, P. J.; Dachiw, J.; Ambrose, J. M.; Pinto, P. B. (1985). «Effects of the calcium antagonists perhexiline and cinnarizine on vascular and cardiac contractile protein function». The Journal of Pharmacology and Experimental Therapeutics 234 (3): 629-635. PMID 3162016. 
  • López, M. G.; Moro, M. A.; Castillo, C. F.; Artalejo, C. R.; García, A. G. (1989). «Variable, voltage-dependent, blocking effects of nitrendipine, verapamil, diltiazem, cinnarizine and cadmium on adrenomedullary secretion». British Journal of Pharmacology 96 (3): 725-731. PMC 1854390. PMID 2720300. doi:10.1111/j.1476-5381.1989.tb11874.x. 
  • Pukhal'Skaya, T. G.; Kolosova, O. A.; Men'Shikov, M. Y.; Vein, A. M. (2000). «Effects of calcium antagonists on serotonin-dependent aggregation and serotonin transport in platelets of patients with migraine». Bulletin of experimental biology and medicine 130 (7): 633-635. PMID 11140571. 

web.archive.org

who.int